Literature DB >> 31567507

Variation in the Use of Resection for Colorectal Cancer Liver Metastases.

Hayley M Fenton1, John C Taylor1, J Peter A Lodge2, Giles J Toogood2, Paul J Finan1, Alastair L Young2, Eva J A Morris1.   

Abstract

OBJECTIVE: The aim of this study was to investigate variation in the frequency of resections for colorectal cancer liver metastases across the English NHS.
BACKGROUND: Previous research has shown significant variation in access to liver resection surgery across the English NHS. This study uses more recent data to identify whether inequalities in access to liver resection still persist.
METHODS: All adults who underwent a major resection for colorectal cancer in an NHS hospital between 2005 and 2012 were identified in the COloRECTal cancer data Repository (CORECT-R). All episodes of care, occurring within 3 years of the initial bowel operation, corresponding to liver resection were identified. RESULT: During the study period 157,383 patients were identified as undergoing major resection for a colorectal tumor, of whom 7423 (4.7%) underwent ≥1 liver resections. The resection rate increased from 4.1% in 2005, reaching a plateau around 5% by 2012. There was significant variation in the rate of liver resection across hospitals (2.1%-12.2%). Patients with synchronous metastases who have their primary colorectal resection in a hospital with an onsite specialist hepatobiliary team were more likely to receive a liver resection (odds ratio 1.22; 95% confidence interval, 1.10-1.35) than those treated in one without. This effect was absent in resection for metachronous metastases.
CONCLUSIONS: This study presents the largest reported population-based analysis of liver resection rates in colorectal cancer patients. Significant variation has been observed in patient and hospital characteristics and the likelihood of patients receiving a liver resection, with the data showing that proximity to a liver resection service is as important a factor as deprivation.

Entities:  

Mesh:

Year:  2019        PMID: 31567507      PMCID: PMC6867670          DOI: 10.1097/SLA.0000000000003534

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


Colorectal cancer (CRC) is a common disease in the UK,[1] and prognosis is poor if, at diagnosis, the disease has metastasized. Unfortunately, this is all too common with approximately 20% of the 42,000 people diagnosed annually[1] having metastatic disease at presentation[2-4] and up to 50% subsequently going on to develop it during the course of their illness.[5] UK outcomes from CRC are known to lag behind many economically comparable countries[6] and as this may, at least in part, be because of poorer outcomes for individuals who present with late stage disease, optimizing their care is a priority. In England, of the 35,000 people diagnosed with CRC, <60% undergo surgical resection of the primary tumor: about 21,000 cases per annum. It is estimated that at least 15% to 20% of patients with metastases in the liver may be eligible for potentially curative liver resection.[7-9] The National Institute of Health and Clinical Excellence guidelines recommend liver resection as the treatment of choice for metastatic disease in patients where this is possible and 10-year survival following such operations is almost 25%.[10] Unfortunately, previous studies[11-13] have shown that the rates of resection for CRC liver metastases (CRCLM) vary significantly across the English National Health Service (NHS) indicating there may be considerable variation in the decision-making process as to who is, and is not, eligible for resection and who is referred to a specialist liver team.[12] The majority of the available evidence dates from >10 years ago so more contemporary data are urgently required to address the persistent concern that there may still be some patients being denied access to a specialist liver services and potentially curative treatments.[13] This population-based study aims, therefore, to provide this information by investigating the frequency of surgical resections for CRCLM across the English NHS using the most recently available data. Trends are examined in relation to patient and tumor characteristics to identify whether the trends in likelihood of resection in relation to these factors and hospital of treatment still persist.

METHODS

Study Population and Data Definitions

All adults diagnosed with a first primary CRC [International Classification of Disease (ICD)-10 codes C18-C20], and who had undergone a major resection for their disease in an NHS hospital with a CRC multidisciplinary team (MDT) between January 1, 2005 and December 31, 2012 (to allow 3 years of follow-up until censoring at December 2015), were identified in the COloRECTal cancer data Repository (CORECT-R). This population-based resource[14] contains numerous linked datasets relevant to CRC. For this study, information was derived from a linked National Cancer Registration and Analysis Service and Hospital Episode Statistics (HES) dataset. Information on date of diagnosis, age, sex, deprivation [measured via the income domain of the Index of Multiple Deprivation (IMD) 2010], site of tumor, and stage were extracted from the cancer registry dataset. Where patients had >1 tumor recorded simultaneously, the tumor with the highest stage was selected. Any remaining duplicate patient records were cleaned to select the most relevant tumor for the type of major resection carried out. Information on the type and date of the first major resection surgery following diagnosis was extracted from the HES component of CORECT-R. Major primary resection and liver resection were identified by the appropriate OPCS4.8 codes (Table 1). Primary tumors in the cecum, appendix, ascending colon, hepatic flexure, and transverse colon (ICD-10 codes C18.0-C18.4) were assigned as right-sided colon tumors, whereas tumors in the splenic flexure, descending colon and sigmoid colon (ICD-10 C18.5-C18.7) were assigned as left-sided colon tumors. Tumors in the rectosigmoid (ICD-10 C19) were classified separately because of different characteristics, as were rectal tumors (ICD-10 C20).
TABLE 1

OPCS 4.8 Codes for Major Colorectal Resection and Liver Resection

OPCS CodeDescription
Primary colorectal resection
H04Total excision of colon and rectum
H05Total excision of colon
H06Extended excision of right hemicolon
H07Other excision of right hemicolon
H08Excision of transverse colon
H09Excision of left hemicolon
H10Excision of sigmoid colon
H11Other excision of colon
H29Subtotal excision of colon
H33Excision of rectum
X14Clearance of pelvis
Liver resection
J021Right hemihepatectomy NEC
J022Left hemihepatectomy NEC
J023Resection of segment of liver
J024Wedge excision of liver
J026Extended right hemihepatectomy
J027Extended left hemihepatectomy
J028Other specified partial excision of liver
J029Partial excision of liver unspecified
J031Excision of lesion of liver
J035Excision of multiple lesions of liver
J038Other specified extirpation of lesion of liver
J039Unspecified extirpation of lesion of liver
A Charlson comorbidity index[15] was derived for each individual in the cohort, taking into account diagnoses (excluding cancer) from any hospital admissions in the year before CRC diagnosis. The cancer component of the Charlson index was derived from the cancer registry information found in CORECT-R and the score for any other cancers in the year before CRC was added to that obtained from HES data. The Charlson score was categorized as: 0, 1, 2, and ≥3 with higher scores indicating greater comorbidity. In the English NHS, a Trust is an organization, comprising ≥1 hospitals that provide care to patients in a city or region. In this article, we have used the term “hospital” in place of Trust. Data regarding whether the initial colorectal resection was carried out within a hospital with an onsite hepatobiliary team (HBT) were obtained from the Organizational Survey 2016, carried out by the National Bowel Cancer Audit (NBOCA).[16] As the survey is a snapshot, carried out at a date outside of the range of this dataset, the location of HBTs may change with service redesign. The survey results were checked against activity in the HES data. Liver center status was retained for hospitals where >80% of liver resections were carried out in the same hospital as patients’ colorectal primary resection, and where hepatic resection activity was consistent across the whole study period. This provided good agreement with the Organizational Survey.

Primary Endpoints

The rate of liver resection was compared across NHS hospitals, to ascertain whether there is significant variation in the surgical management of CRC liver metastases between different providers. Analyses were undertaken with and without adjustment for casemix.

Statistical Methods

The frequency of liver resections was assessed in relation to the year of CRC resection, patient age, sex, site and stage of the primary tumor at diagnosis, IMD quintile, Charlson score, region (based on the Cancer Alliance or Vanguard that the hospital resides in), and the hospital where the initial colorectal resection took place. The statistical significance of any differences in liver resection rates across patient characteristics and between hospitals were assessed using the chi-square test. Multilevel binary logistic regression was used to determine factors associated with the use of resection for CRCLM, with a hierarchy of patients (level 1) clustered within hospitals (level 2), clustered further into regional Cancer Alliances (level 3). Explanatory variables in the risk-adjusted model were age at resection, sex, IMD quintile, primary tumor site, year of primary major colorectal resection, Charlson comorbidity score, stage at diagnosis, and whether the hospital was a liver center. Regression analysis was also repeated for those diagnosed with synchronous metastatic disease (Stage IV at diagnosis) and those who developed metachronous metastatic disease (Stages I-III at diagnosis). Funnel plots were constructed to show the variation across hospitals and Cancer Alliances using the Spiegelhalter approach[17] and those hospitals or Alliances outside of the 99.8% control limits were considered outliers.

RESULTS

Study Population

During the period January 1, 2005 to December 31, 2012, 157,383 patients were identified as undergoing major resection for a colorectal tumor, the characteristics of which are outlined in Table 2. Of these 7423 (4.7%) underwent ≥1 liver resections within 3 years of their primary colorectal resection.
TABLE 2

Characteristics of the Study Population

No Resection (n = 149,960)Liver Resection (n = 7423)Total (n = 157,383)
Tumor site
 Colon101,133 (67.4)4584 (61.8)105,717 (67.2)
 Cecum24,307 (16.2)846 (11.4)25,153 (16)
 Appendix1263 (0.8)42 (0.6)1305 (0.8)
 Ascending colon14,585 (9.7)481 (6.5)15,066 (9.6)
 Hepatic flexure4724 (3.2)208 (2.8)4932 (3.1)
 Transverse colon8709 (5.8)306 (4.1)9015 (5.7)
 Splenic flexure3640 (2.4)189 (2.5)3829 (2.4)
 Descending colon4623 (3.1)228 (3.1)4851 (3.1)
 Sigmoid colon33,601 (22.4)2078 (28)35,679 (22.7)
 Overlapping/unspecified lesion of colon5681 (3.8)206 (2.8)5887 (3.7)
 Rectosigmoid10,786 (7.2)730 (9.8)11,516 (7.3)
 Rectum38,041 (25.4)2109 (28.4)40,150 (25.5)
Sex
 Male83,603 (55.8)4660 (62.8)88,263 (56.1)
 Female66,357 (44.2)2763 (37.2)69,120 (43.9)
Age at primary colorectal resection
 ≤6028,511 (19)2466 (33.2)30,977 (19.7)
 61–7042,715 (28.5)2777 (37.4)45,492 (28.9)
 71–8051,157 (34.1)1950 (26.3)53,107 (33.7)
 >8027,577 (18.4)230 (3.1)27,807 (17.7)
Year of primary colorectal resection
 200515,773 (10.5)682 (9.2)16,455 (10.5)
 200617,676 (11.8)805 (10.8)18,481 (11.7)
 200718,237 (12.2)818 (11)19,055 (12.1)
 200819,116 (12.7)891 (12)20,007 (12.7)
 200919,211 (12.8)1016 (13.7)20,227 (12.9)
 201019,842 (13.2)1069 (14.4)20,911 (13.3)
 201119,951 (13.3)1084 (14.6)21,035 (13.4)
 201220,154 (13.4)1058 (14.3)21,212 (13.5)
Tumor stage at diagnosis
 I19,279 (12.9)252 (3.4)19,531 (12.4)
 II49,202 (32.8)1397 (18.8)50,599 (32.2)
 III47,330 (31.6)2509 (33.8)49,839 (31.7)
 IV9587 (6.4)2236 (30.1)11,823 (7.5)
 Unknown24,562 (16.4)1029 (13.9)25,591 (16.3)
IMD quintile
 1—least deprived33,480 (22.3)1820 (24.5)35,300 (22.4)
 234,022 (22.7)1755 (23.6)35,777 (22.7)
 331,763 (21.2)1528 (20.6)33,291 (21.2)
 427,886 (18.6)1308 (17.6)29,194 (18.5)
 5—most deprived22,809 (15.2)1012 (13.6)23,821 (15.1)
Charlson Comorbidity Index
 0111,599 (74.4)6099 (82.2)117,698 (74.8)
 125,917 (17.3)1031 (13.9)26,948 (17.1)
 27668 (5.1)215 (2.9)7883 (5.0)
 ≥34776 (3.2)78 (1.1)4854 (3.1)

Values in parentheses are percentages.

There were 117 patients who had 2 liver resections within 90 days of each other, suggesting a planned 2-stage liver resection. These are therefore treated as 1 resection episode. There were 750 patients who suffered disease recurrence requiring a further resection within the 3-year period. Overall, there were 6673 patients (89.9%) having 1 resection episode, 692 (9.3%) having 2 resection episodes, and 58 (0.8%) having ≥3, giving a total of 8234 liver resection episodes. Most patients (6708, 90.4%) received their first liver resection after their primary colorectal resection, 499 (6.7%) had a synchronous liver resection with their primary colorectal resection and a small minority (216, 2.9%) had their first liver resection carried out before their major colorectal resection. Overall, 2236 (18.9%) of patients who presented with synchronous metastases, received a liver resection within 3 years of their primary colorectal resection. Median time from primary colorectal resection to first liver resection was 270 days.

Variation in Resection Rates Over Time

The percentage of patients receiving liver resection increased between 2005 and 2012 and appeared to have reached a stable figure of around 5% for all patients who underwent a major resection for CRC during the last 4 years of the study period (Fig. 1). The Charlson comorbidity index of the overall study population increased over time with the proportion of patients with ≥1 comorbidity increasing from 22.8% to 25.2% during the course of this study period.
FIGURE 1

Percentage of patients who receive a major resection for colorectal cancer, and who go on to have a hepatic resection, by the year of the primary colorectal resection.

Percentage of patients who receive a major resection for colorectal cancer, and who go on to have a hepatic resection, by the year of the primary colorectal resection. The data suggest that the proportion of liver resections carried out that were classified as major resections (hemihepatectomies and extended hemihepatectomies), reduced over the study period from 48.2% to 39.9% (P < 0.001, Supplementary Table 1).

Variation in Resection Rates Across Providers

The bar chart and organizational funnel plot (Fig. 2) show the variation in the rate of hepatic resection between different hospitals for the more recent time period, 2009 to 2012. There was a large degree of variation in the proportion of patients having a liver resection by the hospital where their primary tumor was treated, suggesting a difference in referral pathways between hospitals, with crude rates between 1.9% and 16.7% (P ≤ 0.001, Fig. 2A) and risk-adjusted rates ranging from 2.1% to 12.2% (Fig. 2B). Four hospitals were outliers (falling outside the 99.8% control limits on the funnel plot) with 2 having higher than expected rates of liver resection, and 2 having lower than expected rates. By Cancer Alliance (Supplementary Fig. 1), the crude rate ranged from 4.2% to 7.1% (P ≤ 0.001), with a similar risk-adjusted rate of 4.1% to –7.0%.
FIGURE 2

Variation in the proportion of patients receiving a liver resection within three years, by the hospital carrying out their primary colorectal resection, (A) crude rate, (B) risk-adjusted funnel plot.

Variation in the proportion of patients receiving a liver resection within three years, by the hospital carrying out their primary colorectal resection, (A) crude rate, (B) risk-adjusted funnel plot. Analysis by the regional Cancer Alliance, within which the patient is treated for their primary colorectal resection shows that the rate of major liver resection (hemihepatectomy and extended hemihepatectomy) varied between 28% and 58% of all liver resections carried out (P < 0.001). This suggests there are regional differences in the surgical treatment of liver metastases. There are also differences in the type of liver resection carried out, depending on whether patients had their primary colorectal tumor removed at a hospital with a specialist liver center onsite. The major liver resection rate was 36.1% for liver centers compared to 41.1% for those treated for their colorectal primary in a hospital without a liver centre (P < 0.001)

Variation in Resection Rates by Patient Characteristics

Table 3 shows the results of the logistic regression model used to determine the odds of liver resection. There was no significant difference in the rate by year of primary resection in the adjusted model. The likelihood of liver resection decreased significantly with increasing age [odds ratio (OR) per 10-year increase 0.64; 95% confidence interval (CI), 0.62–0.65], with increasing deprivation level (OR for most deprived quintile compared to most affluent 0.76; 95% CI, 0.70–0.83)) and with increasing Charlson co-morbidity score (OR for Charlson score ≥3 compared to score of zero 0.43; 95% CI, 0.34–0.53). Women were less likely to receive a resection (OR 0.77; 95% CI, 0.73–0.81).
TABLE 3

Odds of Having a Liver Resection Within 3 Years of Primary Colorectal Tumor Resection

Unadjusted Odds Ratio95% Confidence IntervalPP Across GroupsAdjusted Odds Ratio95% Confidence IntervalPP Across Groups
Year of resection of colorectal primary1.031.021.05<0.001<0.0011.001.001.020.1550.155
Primary resection carried out in hospital with liver center1.291.231.37<0.001<0.0011.221.101.35<0.001<0.001
Age at resection of colorectal primary (per 10-y increase)0.580.560.59<0.001<0.0010.630.620.65<0.001<0.001
Sex<0.001<0.001
 Male1.001.00
 Female0.750.710.78<0.0010.770.730.81<0.001
IMD quintile<0.001<0.001
 1—least deprived1.001.00
 20.950.891.010.1270.970.901.030.307
 30.880.830.950.0010.900.830.970.004
 40.860.800.93<0.0010.870.810.94<0.001
 5—most deprived0.820.750.88<0.0010.760.700.83<0.001
Stage of primary tumor at diagnosis<0.001<0.001
 I1.001.00
 II2.171.902.49<0.0012.662.323.04<0.001
 III4.063.564.62<0.0014.463.915.09<0.001
 IV17.8415.6320.37<0.00120.1417.6023.04<0.001
 unknown3.212.793.68<0.0012.972.573.43<0.001
Tumour site<0.001<0.001
 Right colon1.001.00
 Left colon1.701.601.80<0.0011.661.561.77<0.001
 Rectosigmoid1.921.762.10<0.0011.901.732.08<0.001
 Rectum1.581.481.68<0.0011.601.491.71<0.001
 Colon unknown1.030.891.190.6741.060.911.230.469
Charlson comorbidity score<0.001<0.001
 01.001.00
 10.730.680.78<0.0010.850.790.91<0.001
 20.510.450.59<0.0010.680.590.79<0.001
 ≥30.300.240.37<0.0010.430.340.53<0.001
The odds of resection were higher for tumors in the rectosigmoid (OR 1.90; 95% CI, 1.73–2.08), rectum (OR 1.60; 95% CI, 1.49–1.71) and left colon (OR 1.66; 95% CI, 1.56–1.77) compared to the right colon. The odds also increased with advancing stage of the disease at presentation (OR Stage IV vs Stage I 20.14; 95% CI, 17.60–23.04). In addition to the patient characteristics listed, elements of the treatment pathway affected the likelihood of resection. Patients who have their primary colorectal resection in a hospital with a liver center were more likely to receive a liver resection (OR 1.22; 95% CI; 1.10–1.35). This may be because of a higher proportion of liver resections taking place synchronously to their bowel resection for these patients (18%) compared to those receiving their bowel resection in a hospital without a specialist onsite liver center (3%). When the logistic regression model was run to only include patients at Stages I–III at diagnosis, this effect was observed in the unadjusted model (Supplementary Table 3, OR 1.10; 95% CI ,1.02–1.19) but was no longer significant following risk-adjustment, and was only seen for those patients with synchronous metastases (Supplementary Table 2).

DISCUSSION

This study presents the most up-to-date and largest reported population-based analysis of liver resection rates in CRC patients since Morris et al.[11] It includes resection for both synchronous and metachronous metastatic disease and covers all patients receiving a major primary resection for CRC within the English NHS. Despite a plateau being observed in the percentage of CRC patients undergoing a liver resection, significant differences in the likelihood of liver resection continue to be observed for different patient characteristics, hospitals, and Cancer Alliances. Women were less likely to receive a liver resection than men and this was independent of tumor location, stage, age, comorbidity, and deprivation quintile. Although the models used are not directly comparable, this reflects the findings of the previous analysis[11] showing this trend has changed little over time. It has also been confirmed in several other studies.[11,13,18] The lower likelihood of liver resection for women was present for all disease stages except for presentation at Stage I and so potential explanations such as differing surveillance or referral patterns between men and women should be explored in more detail. Older patients were still less likely to receive a liver resection,[11,18-20] despite data showing they can achieve good outcomes.[21] Although patients aged >70 years made up 51.4% of those undergoing major colorectal resection, they accounted for only 29.4% of those undergoing liver resection. It is important to note, however, that in this >70s group, liver resection rates have more than doubled over time, from 1.2% in 1998 to 2004 to 2.8% in 2005 to 2012 suggesting management patterns may have changed. The rate of major liver resection decreased over the period, from 48.2% to 33.8% of all liver resections carried out. Increasing deprivation was also associated with a reduced likelihood of receiving a liver resection[11,20], with those in the most deprived quintile being 24% less likely to receive a resection than those in the most affluent quintile, as was increasing comorbidity.[11,18] In addition, these data demonstrate that anatomical location of the CRC may influence the likelihood of liver resection as the odds of receiving a resection was lowest for right-sided primary tumors. Such an observation was also noted in 2 Swedish studies.[2,18] There has also been a change in the management of patients with synchronous metastases (Stage IV at presentation), with the proportion of these who receive liver resection surgery >doubling from 8.0% for the period 1998 to 2004 to 18.9% in 2005 to 2012.[11] Patients who received their major primary colorectal resection in a hospital designated in this study as a liver center were 22% more likely to receive a liver resection compared to those who had to be referred on elsewhere, suggesting that referral pathways may not be working as efficiently as they should be and patients are missing out on access to treatment depending on their proximity to a hospital with a liver center. This replicates findings from a study using HES data, which examined 4547 patients who underwent major bowel resection and had synchronous metastases at diagnosis; patients treated in a hospital with an onsite hepatobiliary center were more likely to receive a liver resection.[13] Our study confirmed this in a population of people with both synchronous and metachronous metastases and found that the increased likelihood of liver resection for patients receiving their bowel resection in a hospital with an onsite specialist liver team was present for patients at Stages I–III at diagnosis in the nonadjusted model, but this was no longer significant following risk-adjustment. However patients with synchronous metastases were 43% more likely to receive a liver resection if they had their primary tumor resected in a hospital with an onsite liver center. Numerous studies have now shown that both surgeon and hospital specialization may be associated with improved surgical outcomes, especially for complex procedures.[22-26] This study is an important contribution to that evidence base as, across the whole population, it suggests that proximity to a liver center is as important a factor as socioeconomic deprivation when it comes to the likelihood of receiving a liver resection. Around 35% of patients with Stage IV disease treated in a liver center received their liver resection before or at the same time as their major bowel resection, compared to 11% of patients in nonliver centers, showing a large degree of variation in the treatment pathway for synchronous metastases. Streamlining the referral process may lead to more patients being eligible for synchronous resection, which may improve outcomes. Although linkage of the cancer registry and HES data allows full coverage of all CRC patients, there are some limitations of the study. The routine nature of the data means that there is no information as to extent of liver disease, chemotherapy status, treatment intent, or patient choice so we do not know which patients were potentially eligible for liver resection but did not undergo surgery. However, it is unlikely that the burden of liver disease varies substantially across hospitals, once adjustment for other patient and tumor characteristics is performed and so the variation highlighted remains valid. In conclusion, a large degree of variation is still present in the rates of resection by hospital, even allowing for differences in age, stage, deprivation quintile, Charlson, tumor site, comorbidity index, year of primary resection, and whether the hospital has a liver center. This suggests that there is still variation in access to treatment for patients with both synchronous and metachronous hepatic disease and, in light of the poorer outcomes reported within the UK, such variation deserves further urgent investigation. Despite a plateau in liver resection rates, clinicians should not become complacent in the management of CRCLM patients. Significant variations have been observed in patient and hospital characteristics and the likelihood of patients receiving a liver resection. Likely there are multiple factors influencing this; however, further work is needed to elucidate the reasons for this variation, as addressing this has a significant potential to improve patient outcomes.
  23 in total

1.  High-volume surgeons vs high-volume hospitals: are best outcomes more due to who or where?

Authors:  Paul G Toomey; Anthony F Teta; Krishen D Patel; Sharona B Ross; Alexander S Rosemurgy
Journal:  Am J Surg       Date:  2015-11-02       Impact factor: 2.565

2.  Surgical management and outcomes of colorectal cancer liver metastases.

Authors:  E J A Morris; D Forman; J D Thomas; P Quirke; E F Taylor; L Fairley; B Cottier; G Poston
Journal:  Br J Surg       Date:  2010-07       Impact factor: 6.939

3.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

4.  Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?

Authors:  John M Creasy; Eran Sadot; Bas Groot Koerkamp; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Vinod P Balachandran; T Peter Kingham; Ronald P DeMatteo; Peter J Allen; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  Surgery       Date:  2018-02-15       Impact factor: 3.982

5.  Influence of national centralization of oesophagogastric cancer on management and clinical outcome from emergency upper gastrointestinal conditions.

Authors:  S R Markar; H Mackenzie; T Wiggins; A Askari; A Karthikesalingam; O Faiz; S M Griffin; J D Birkmeyer; G B Hanna
Journal:  Br J Surg       Date:  2017-11-20       Impact factor: 6.939

6.  A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer.

Authors:  J Leporrier; J Maurel; L Chiche; S Bara; P Segol; G Launoy
Journal:  Br J Surg       Date:  2006-04       Impact factor: 6.939

7.  Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates.

Authors:  H Møller; S Richards; N Hanchett; S P Riaz; M Lüchtenborg; L Holmberg; D Robinson
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

8.  Patterns of metastasis in colon and rectal cancer.

Authors:  Matias Riihimäki; Akseli Hemminki; Jan Sundquist; Kari Hemminki
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

9.  Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases.

Authors:  A E Vallance; J vanderMeulen; A Kuryba; I D Botterill; J Hill; D G Jayne; K Walker
Journal:  Br J Surg       Date:  2017-03-02       Impact factor: 6.939

10.  Surgeon specialization and operative mortality in United States: retrospective analysis.

Authors:  Nikhil R Sahni; Maurice Dalton; David M Cutler; John D Birkmeyer; Amitabh Chandra
Journal:  BMJ       Date:  2016-07-21
View more
  7 in total

1.  Changing patterns of multidisciplinary team treatment, early mortality, and survival in colorectal cancer.

Authors:  David M Layfield; Karen G Flashman; Sara Benitez Majano; Asha Senapati; Christopher Ball; John A Conti; Jim S Khan; Daniel P O'Leary
Journal:  BJS Open       Date:  2022-09-02

2.  Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study.

Authors:  Pia Osterlund; Tapio Salminen; Leena-Maija Soveri; Raija Kallio; Ilmo Kellokumpu; Annamarja Lamminmäki; Päivi Halonen; Raija Ristamäki; Eila Lantto; Aki Uutela; Emerik Osterlund; Ali Ovissi; Arno Nordin; Eetu Heervä; Kaisa Lehtomäki; Jari Räsänen; Maija Murashev; Laura Aroviita; Antti Jekunen; Reneé Lindvall-Andersson; Paul Nyandoto; Juha Kononen; Anna Lepistö; Tuija Poussa; Timo Muhonen; Annika Ålgars; Helena Isoniemi
Journal:  Lancet Reg Health Eur       Date:  2021-01-29

3.  Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study.

Authors:  Malin Ljunggren; Caroline E Weibull; Emma Rosander; Gabriella Palmer; Bengt Glimelius; Anna Martling; Caroline Nordenvall
Journal:  BMC Cancer       Date:  2022-08-19       Impact factor: 4.638

4.  HOXD9 promote epithelial-mesenchymal transition and metastasis in colorectal carcinoma.

Authors:  Mengwei Liu; Yizhi Xiao; Weimei Tang; Jiaying Li; Linjie Hong; Weiyu Dai; Wenjing Zhang; Ying Peng; Xiaosheng Wu; Jing Wang; Yaying Chen; Yang Bai; Jianjiao Lin; Qiong Yang; Yusi Wang; Zhizhao Lin; Side Liu; Jing Xiong; Jide Wang; Li Xiang
Journal:  Cancer Med       Date:  2020-04-12       Impact factor: 4.452

5.  Data Resource Profile: The COloRECTal cancer data repository (CORECT-R).

Authors:  Amy Downing; Peter Hall; Rebecca Birch; Elizabeth Lemmon; Paul Affleck; Hannah Rossington; Emily Boldison; Paul Ewart; Eva J A Morris
Journal:  Int J Epidemiol       Date:  2021-11-10       Impact factor: 7.196

6.  Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients.

Authors:  Nina D Arhin; Chan Shen; Christina E Bailey; Lea K Matsuoka; Alexander T Hawkins; Andreana N Holowatyj; Kristen K Ciombor; Michael B Hopkins; Timothy M Geiger; Audrey E Kam; Marc T Roth; Cody M Lebeck Lee; Michael Lapelusa; Arvind Dasari; Cathy Eng
Journal:  Cancer Med       Date:  2021-06-16       Impact factor: 4.452

7.  Liver-First Approach for Synchronous Colorectal Metastases: Analysis of 7360 Patients from the LiverMetSurvey Registry.

Authors:  Felice Giuliante; Luca Viganò; Agostino M De Rose; Darius F Mirza; Réal Lapointe; Gernot Kaiser; Eduardo Barroso; Alessandro Ferrero; Helena Isoniemi; Santiago Lopez-Ben; Irinel Popescu; Jean-Francois Ouellet; Catherine Hubert; Jean-Marc Regimbeau; Jen-Kou Lin; Oleg G Skipenko; Francesco Ardito; René Adam
Journal:  Ann Surg Oncol       Date:  2021-07-01       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.